The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarkers of response to neoadjuvant atezolizumab with gemcitabine and cisplatin in muscle-invasive bladder cancer.
 
Michael Lattanzi
No Relationships to Disclose
 
Alexander Solovyov
No Relationships to Disclose
 
Jayon Lihm
No Relationships to Disclose
 
Colleen Quinlan
No Relationships to Disclose
 
Karissa Whiting
No Relationships to Disclose
 
Hao Li
No Relationships to Disclose
 
Hikmat A. Al-Ahmadie
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono; Janssen Biotech; PAIGE.AI
 
Min Yuen Teo
Consulting or Advisory Role - Janssen Oncology
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Pharmacyclics (Inst)
 
David Henry Aggen
Consulting or Advisory Role - Astellas Pharma; Boehringer Ingelheim; Seagen
Patents, Royalties, Other Intellectual Property - University of Illinois - Urbana Champaign
 
Irina Ostrovnaya
No Relationships to Disclose
 
Ashley Marie Regazzi
No Relationships to Disclose
 
Marwah Jihad
No Relationships to Disclose
 
Dean F. Bajorin
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Dragonfly Therapeutics; Fidia Farmaceutici S. p. A.; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)
Travel, Accommodations, Expenses - Merck
 
Arjun Vasant Balar
Leadership - GT Biopharma
Stock and Other Ownership Interests - GT Biopharma
Honoraria - AstraZeneca/MedImmune; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb/Celgene; Cerulean Pharma; Dragonfly Therapeutics; Genentech/Roche; GlaxoSmithKline; Incyte; Merck; Nektar; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Seagen
 
Amir Mortazavi
Honoraria - Motive Medical Intelligence
Consulting or Advisory Role - Debiopharm Group; Pfizer; Seagen
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst)
 
Taha Merghoub
Stock and Other Ownership Interests - Imvaq therapeutics
Honoraria - Leap Therapeutics; Pfizer
Consulting or Advisory Role - ImmunoGenesis; Immunos Therapeutics
Research Funding - BMS; Surface Oncology
Patents, Royalties, Other Intellectual Property - inventor on patent applications related to work on oncolytic viral therapy, alphavirus-based vaccines, neo-antigen modeling, CD40, GITR, OX40, PD-1 and CTLA-4.
 
Gopa Iyer
Consulting or Advisory Role - Basilea; Bayer; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Speakers' Bureau - Gilead Sciences; Lynx Group
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Jonathan E. Rosenberg
Honoraria - Clinical Care Options; EMD Serono; Intellisphere; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource; Research To Practice; UpToDate
Consulting or Advisory Role - Alligator Bioscience; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Hengrui Pharmaceutical; Immunomedics; Infinity Pharmaceuticals; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Tyra Biosciences
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); QED Therapeutics (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
 
Benjamin Greenbaum
Leadership - ROME Therapeutics; Sibyl Analytics
Stock and Other Ownership Interests - ROME Therapeutics; Sibyl Analytics
Consulting or Advisory Role - DarwinHealth; Merck Sharp & Dohme
Patents, Royalties, Other Intellectual Property - ROME Therapeutics
 
Samuel Aaron Funt
Employment - ByHeart (I)
Stock and Other Ownership Interests - Allogene Therapeutics; Doximity; IconOVir Bio; Kite, a Gilead company; Kronos Bio; Neogene Therapeutics; Urogen pharma; Vida Ventures
Consulting or Advisory Role - Immunai; Merck
Research Funding - AstraZeneca (Inst); Decibel Therapeutics (Inst); Genentech/Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb